검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-8 · 마지막 7월 21일
현재 선택: 4개 · 임상 갱신 필요 2개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | lymphodepleting chemotherapy (lymphodepleting chemotherapy) Hemogenyx Pharmaceuticals LLC·Non-Hodgkin Lymphoma ORR 80.3% | |||
|---|---|---|---|---|
Overview Program | Brentuximab Vedotin | Polatuzumab Vedotin | Zanubrutinib | lymphodepleting chemotherapy |
Overview Company | Seagen / Takeda | Roche / Genentech | Juan P. Alderuccio, MD | Hemogenyx Pharmaceuticals LLC |
Overview Modality | ADC | ADC | ANTIBODY | ANTIBODY |
Overview Target | Hodgkin Disease | FRα | CNS Lymphoma | Non-Hodgkin Lymphoma |
Overview Indication | Hodgkin Lymphoma | Relapsed or Refractory Follicular Lymphoma, Relapsed or Refractory Diffuse Large B-Cell Lymphoma | CNS Lymphoma | Clear Cell Carcinoma; Phase 1 |
Overview Phase | APPROVED | PHASE_3 | PHASE_3 | PHASE_3 |
Overview Status | ACTIVE | RECRUITING | RECRUITING | ACTIVE |
MoA Mechanism | targeting specific cell surface antigens, many ADCs have also been associated with unique toxicities related to the antigen | targeting specific cell surface antigens, many ADCs have also been associated with unique toxicities related to the antigen | inhibits B-cell receptor signaling | CAR-T cell therapy for GAD65 antibody-mediated cerebellar ataxia |
MoA Biomarker | biomarker-driven treatment in NHL, including resistance mechanisms, toxicity management, optimal therapeutic | CD20 expression | biomarker to guide treatment duration in two prospective trials of venetoclax- and sonrotoclax-based triplets | biomarkers exist to predict toxicity risk, underscoring the need for further research |
PK/PD Half-life | — | 12.2 h | — | — |
PK/PD Species | Mouse | Rat | Rat | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro | Rat, In vitro | Rat | Mouse |
PK/PD Experiment | pd | pharmacokinetic | PK | PD |
Toxicology Species | Cynomolgus monkey, Mouse, Rat | Cynomolgus monkey, Mouse, Rat | Rat | Mouse |
Toxicology Animal (cat.) | Mouse, Rat, NHP | Mouse, Rat, NHP | Rat | Mouse |
Toxicology Major finding | Hepatotoxicity : Monitor liver enzymes and bilirubin ( 5 | Hepatotoxicity: Monitor liver enzymes and bilirubin | Hepatotoxicity, Including Drug-Induced Liver Injury : Monitor hepatic function throughout t | thrombocytopenia) but achieved a best response of morphologic leukemia-free state on day 14 foll |
Toxicology CRS | — | — | — | Reported |
Clinical Primary efficacy | ORR 86% | ORR 100% | ORR 95.2% | ORR 80.3% |
Clinical ORR | 86% | 100.0% | 95.2% | 80.3% |
Clinical PFS | — | — | 61.4 | 9.03 |
Clinical OS | — | — | NA | NA |
Clinical Result source | ClinicalTrials.gov NCT01712490 | ClinicalTrials.gov NCT02611323 | ClinicalTrials.gov NCT02343120 | ClinicalTrials.gov NCT03483103 |
Clinical Data Tier / Score | B · 89 | S · 92 | C · 78 | C · 75 |
Clinical Program phase | APPROVED | PHASE_3 | PHASE_3 | PHASE_3 |
Clinical Clinical sync | 2026년 7월 18일 (8일 전) | 2026년 7월 18일 (8일 전) | 2026년 7월 8일 (19일 전 · 갱신 권장) | 2026년 7월 9일 (18일 전 · 갱신 권장) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-8 · 마지막 7월 21일
현재 선택: 4개 · 임상 갱신 필요 2개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | lymphodepleting chemotherapy (lymphodepleting chemotherapy) Hemogenyx Pharmaceuticals LLC·Non-Hodgkin Lymphoma ORR 80.3% | |||
|---|---|---|---|---|
Overview Program | Brentuximab Vedotin | Polatuzumab Vedotin | Zanubrutinib | lymphodepleting chemotherapy |
Overview Company | Seagen / Takeda | Roche / Genentech | Juan P. Alderuccio, MD | Hemogenyx Pharmaceuticals LLC |
Overview Modality | ADC | ADC | ANTIBODY | ANTIBODY |
Overview Target | Hodgkin Disease | FRα | CNS Lymphoma | Non-Hodgkin Lymphoma |
Overview Indication | Hodgkin Lymphoma | Relapsed or Refractory Follicular Lymphoma, Relapsed or Refractory Diffuse Large B-Cell Lymphoma | CNS Lymphoma | Clear Cell Carcinoma; Phase 1 |
Overview Phase | APPROVED | PHASE_3 | PHASE_3 | PHASE_3 |
Overview Status | ACTIVE | RECRUITING | RECRUITING | ACTIVE |
MoA Mechanism | targeting specific cell surface antigens, many ADCs have also been associated with unique toxicities related to the antigen | targeting specific cell surface antigens, many ADCs have also been associated with unique toxicities related to the antigen | inhibits B-cell receptor signaling | CAR-T cell therapy for GAD65 antibody-mediated cerebellar ataxia |
MoA Biomarker | biomarker-driven treatment in NHL, including resistance mechanisms, toxicity management, optimal therapeutic | CD20 expression | biomarker to guide treatment duration in two prospective trials of venetoclax- and sonrotoclax-based triplets | biomarkers exist to predict toxicity risk, underscoring the need for further research |
PK/PD Half-life | — | 12.2 h | — | — |
PK/PD Species | Mouse | Rat | Rat | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro | Rat, In vitro | Rat | Mouse |
PK/PD Experiment | pd | pharmacokinetic | PK | PD |
Toxicology Species | Cynomolgus monkey, Mouse, Rat | Cynomolgus monkey, Mouse, Rat | Rat | Mouse |
Toxicology Animal (cat.) | Mouse, Rat, NHP | Mouse, Rat, NHP | Rat | Mouse |
Toxicology Major finding | Hepatotoxicity : Monitor liver enzymes and bilirubin ( 5 | Hepatotoxicity: Monitor liver enzymes and bilirubin | Hepatotoxicity, Including Drug-Induced Liver Injury : Monitor hepatic function throughout t | thrombocytopenia) but achieved a best response of morphologic leukemia-free state on day 14 foll |
Toxicology CRS | — | — | — | Reported |
Clinical Primary efficacy | ORR 86% | ORR 100% | ORR 95.2% | ORR 80.3% |
Clinical ORR | 86% | 100.0% | 95.2% | 80.3% |
Clinical PFS | — | — | 61.4 | 9.03 |
Clinical OS | — | — | NA | NA |
Clinical Result source | ClinicalTrials.gov NCT01712490 | ClinicalTrials.gov NCT02611323 | ClinicalTrials.gov NCT02343120 | ClinicalTrials.gov NCT03483103 |
Clinical Data Tier / Score | B · 89 | S · 92 | C · 78 | C · 75 |
Clinical Program phase | APPROVED | PHASE_3 | PHASE_3 | PHASE_3 |
Clinical Clinical sync | 2026년 7월 18일 (8일 전) | 2026년 7월 18일 (8일 전) | 2026년 7월 8일 (19일 전 · 갱신 권장) | 2026년 7월 9일 (18일 전 · 갱신 권장) |
추천 비교
추천 비교